Zealand Pharma and OTR Therapeutics have entered a multi-programme strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases. The collaboration will combine Zealand Pharma’s experience in obesity and metabolic health with OTR Therapeutics’ oral small-molecule platform. "The multi-programme collaboration will expand our metabolic health pipeline into oral small-molecule therapeutics for targets where […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!